XML 30 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unaudited Condensed Consolidated Statement of Changes in Equity - USD ($)
$ in Millions
Total
Adjustment to closing equity in respect of hyperinflation
Adjusted balance
Equity attributable to parent company shareholders
Equity attributable to parent company shareholders
Adjustment to closing equity in respect of hyperinflation
Equity attributable to parent company shareholders
Adjusted balance
Share capital
Share capital
Adjusted balance
Share premium
Share premium
Adjusted balance
Other reserves
Other reserves
Adjusted balance
Total retained earnings
Total retained earnings
Adjustment to closing equity in respect of hyperinflation
Total retained earnings
Adjusted balance
Own shares
Own shares
Adjusted balance
Other retained earnings
Other retained earnings
Adjustment to closing equity in respect of hyperinflation
Other retained earnings
Adjusted balance
Non-controlling interests
Non-controlling interests
Adjustment to closing equity in respect of hyperinflation
Non-controlling interests
Adjusted balance
Beginning balance at Jun. 30, 2022 [1] $ 11,511     $ 9,435     $ 875   $ 1,635   $ 658   $ 6,267     $ (2,223)   $ 8,490     $ 2,076    
Other(2) [2] 0     0     (7)   (14)   4   17     17   0     0    
Profit for the period 2,841 [3],[4],[5]     2,709                 2,709         2,709     132    
Other comprehensive loss (520) [4]     (459)             (107)   (352)         (352)     (61)    
Total comprehensive (loss)/income for the period 2,321 [4]     2,250             (107)   2,357         2,357     71    
Employee share schemes 39     39                 39     22   17          
Share-based incentive plans 31     31                 31         31          
Share-based incentive plans in respect of associates 3     3                 3         3          
Share-based payments and purchase of own shares in respect of subsidiaries 2     1                 1         1     1    
Associates' transactions with non-controlling interests (14)     (14)                 (14)         (14)          
Unclaimed dividend 1     1                 1         1     0    
Change in fair value of put option (5)     (5)                 (5)         (5)          
Share buyback programme (775)     (775)     (5)       5   (775)         (775)          
Dividend declared in the period (1,275)     (1,200)                 (1,200)         (1,200)     (75)    
Ending balance at Dec. 31, 2022 [1] 11,839     9,766     863   1,621   560   6,722     (2,184)   8,906     2,073    
Beginning balance at Jun. 30, 2023 11,709 [6] $ 51 $ 11,760 9,856 [1] $ 41 $ 9,897 898 [1] $ 898 1,703 [1] $ 1,703 665 [1] $ 665 6,590 [1] $ 41 $ 6,631 (2,286) [1] $ (2,286) 8,876 [1] $ 41 $ 8,917 1,853 [1] $ 10 $ 1,863
Profit for the period 2,342     2,210                 2,210         2,210     132    
Other comprehensive loss (93)     (84)             (168)   84         84     (9)    
Total comprehensive (loss)/income for the period 2,249     2,126             (168)   2,294         2,294     123    
Employee share schemes 34     34                 34     30   4          
Share-based incentive plans 24     24                 24         24          
Share-based incentive plans in respect of associates 2     2                 2         2          
Tax on share-based incentive plans (7)     (7)                 (7)         (7)     0    
Unclaimed dividend 1     1                 1         1     0    
Change in fair value of put option 40     40                 40         40          
Share buyback programme (977)     (977)     (5)       5   (977)         (977)          
Dividend declared in the period (1,402)     (1,349)                 (1,349)         (1,349)     (53)    
Ending balance at Dec. 31, 2023 $ 11,724     $ 9,791     $ 893   $ 1,703   $ 502   $ 6,693     $ (2,256)   $ 8,949     $ 1,933    
[1] (1) See page F-7 for an explanation under Basis of preparation.
[2] (2) Includes amounts relating to foreign translation differences arising from the retranslation of reserves due to the change in the group’s presentation currency.
[3] (1) See page F-7 for an explanation under Basis of preparation.
[4] (2) See page F-7 for an explanation under Basis of preparation.
[5] (1)See page F-7 for an explanation under Basis of preparation.
[6] (1) See page F-7 for an explanation under Basis of preparation.